Compound for the Treatment of Enteroviruses

Abstract

The present invention relates to the treatment, alleviation, prevention or reduction in the incidence of symptoms, diseases or conditions resulting from or associated with enteroviruses, more particularly the enteroviral infections they cause.

What is claimed is: 
     
         1 . A method for treating, alleviating, or reducing an enteroviral infection caused by a serotype of one or more viruses selected from the group consisting of enterovirus, poliovirus, Human enterovirus B, Human enterovirus C and Human enterovirus D, comprising administering 3-ethoxy-6-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzo[d]isoxazole or a pharmaceutically acceptable salt thereof to a subject suffering from said infection, and further comprising administering a second enteroviral agent. 
     
     
         2 . The method according to  claim 1  further comprising the step of selecting a subject on the basis of requiring treatment, alleviation, prevention or reduction of symptoms, diseases or conditions associated with an enteroviral infection caused by a serotype of one or more viruses selected from the group consisting of enterovirus, poliovirus, Human enterovirus A, Human enterovirus B, Human enterovirus C and Human enterovirus D. 
     
     
         3 . The method according to  claim 1  wherein the poliovirus is poliovirus 1 (PV1). 
     
     
         4 . The method according to  claim 1  wherein the enterovirus is enterovirus 71 (EV71). 
     
     
         5 . The method according to  claim 1  wherein the second anti-enteroviral agent is a 3C protease inhibitor or a 3A targeting compound. 
     
     
         6 . The method according to  claim 1  wherein the second anti-enteroviral agent is selected from the group consisting of a capsid binder, a 3C protease inhibitor, a 3A targeting compound, interferon and a vaccine. 
     
     
         7 . The method according to  claim 1  wherein the second anti-enteroviral agent is selected from the group consisting of pirodavir, pleconaril, V-073, rupintrivir (AG-7088), 2′-C-Met-Cyt, enviroxime, TTP-8307, MDL-860, interferon and a polio vaccine. 
     
     
         8 . The method according to  claim 1  wherein the second anti-enteroviral agent has an unrelated mode of action. 
     
     
         9 . The method according to  claim 1  wherein administering the second an enteroviral agent is by separate, simultaneous or sequential administration. 
     
     
         10 . A composition comprising 3-ethoxy-6-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxyl-benzo[d]isoxazole or a pharmaceutically acceptable salt thereof and a second anti-enteroviral agent. 
     
     
         11 . The composition according to  claim 10  wherein the second anti-enteroviral agent is selected from the group consisting of a capsid binder, a 3C protease inhibitor, a 3A targeting compound, interferon and a vaccine. 
     
     
         12 . The composition according to  claim 10  wherein the second anti-enteroviral agent is selected from the group consisting of pirodavir, pleconaril, V-073, rupintrivir (AG-7088), 2′-C-Met-Cyt, enviroxime, TTP-8307, MDL-860, interferon and a polio vaccine. 
     
     
         13 . The composition according to  claim 10  wherein the second anti-enteroviral agent has an unrelated mode of action to that of 3-ethoxy-6-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxyl-benzo[d]isoxazole or a pharmaceutically acceptable sail thereof. 
     
     
         14 . The composition according to  claim 10  wherein the second anti-enteroviral agent is a 3C protease inhibitor or a 3A targeting compound. 
     
     
         15 . The composition according to  claim 10  wherein the second anti-enteroviral agent is rupintrivir (AG-7088) or enviroxime. 
     
     
         16 . The composition according to  claim 10  further comprising a pharmaceutically-acceptable adjuvant, diluent or carrier. 
     
     
         17 . A composition comprising 3-ethoxy-6-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxyl-benzo[d]isoxazole or a pharmaceutically acceptable salt thereof and interferon, and wherein one or both of the first and second components optionally comprise a pharmaceutically-acceptable adjuvant, diluent or carrier. 
     
     
         18 . A kit comprising a first component and a second component, wherein each component of the kit is provided in a form suitable for administration in conjunction with the other component, the first component comprising 3-ethoxy-6-{241-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxyl-benzo[d]isoxazole or a pharmaceutically acceptable salt thereof, and the second component comprising a second anti-enteroviral agent, and wherein one or both of the first and second components optionally comprise a pharmaceutically-acceptable adjuvant, diluent or carrier. 
     
     
         19 . The kit of  claim 18  wherein the first and second components are provided as separate formulations which may be brought together for use in conjunction with each other in combination therapy. 
     
     
         20 . The kit of  claim 18  wherein the first and second components are packaged together as separate components of a combination pack for use in conjunction with each other in combination therapy. 
     
     
         21 . A method for treating, alleviating, or reducing an enteroviral infection comprising administering 3-ethoxy-6-{ 2 -[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzo[d]isoxazole or a pharmaceutically acceptable salt thereof to a subject suffering from said infection, and further comprising administering a second enteroviral agent selected from the group consisting of a capsid binder, a 3C protease inhibitor, a 3A targeting compound, interferon and a vaccine. 
     
     
         22 . The method of  claim 21  wherein the enteroviral infection is caused by a serotype of one or more species selected from the group consisting of Human enterovirus B, Human enterovirus C and Human enterovirus D. 
     
     
         23 . A method for treating, alleviating, or reducing an enteroviral infection comprising administering 3-ethoxy-6-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzo[d]isoxazole or a pharmaceutically acceptable salt thereof to a subject suffering from said infection, and further comprising administering interferon.